Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
9D3rV2EYFeJVYvAK
